Abstract
Sustained Improvements in Patient-Reported Quality of Life up to 24 Months Post-Treatment with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have